FLKS - Flex Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Flex Pharma, Inc.

31 Street James Avenue
6th Floor
Boston, MA 02116
United States
617-874-1821
http://www.flex-pharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees4

Key Executives

NameTitlePayExercisedYear Born
Dr. William K. McVicarPres, CEO & Director751.11kN/A1958
Dr. Roderick MacKinnonCo-Founder & Co-Chair of Scientific Advisory Board42.13kN/A1956
Mr. John McCabeCFO, Treasurer & Sec.478.12kN/A1970
Dr. Thomas C. WesselOutside Advisor481.16kN/A1956
Dr. Bruce BeanCo-Founder, Co-Chair of Scientific Advisory Board & Board ObserverN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps, spasms, and spasticity associated with neurological conditions and exercise-associated muscle cramps in the United States. It operates in two segments, Consumer Operations and Drug Development. The company's lead drug candidate is FLX-787, a single molecule, chemically synthesized, and dual transient receptor potential V1/A1 ion channel activator, which completed an exploratory Phase II clinical trial in Australia for the treatment of patients with multiple sclerosis. It also offers HOTSHOT, a consumer beverage to prevent and treat exercise associated muscle cramps. The company markets and sells its HOTSHOT products online through its direct-to-consumer Website and through third-party Websites, including a retailer that offers international shipping. Flex Pharma, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.

Corporate Governance

Flex Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.